Method of treating patients with oncological diseases or immune suppressions
SUBSTANCE: invention refers to medicine, namely to oncology, and concerns treating the patients suffering oncological diseases by administering the preparations inducing active cellular immune stimulation. The preparations are administered in the form of lyophilised lysate of gram-positive enteric bacteria enclosed in gelatine capsules. That is combined with correcting intestinal dysbacteriosis, administering antioxidants, vitamins and minerals, as well as nutrient-enriched protein food, amino acid L-arginine, and pectin- and fibre-enriched vegetable food.
EFFECT: method provides higher clinical effectiveness of the patients suffering the oncological diseases with no side effects.
The invention relates to medicine, in particular to Oncology and immunology.
Known cancer treatment and immunodepressed ready cytokines: interferons, interleukins (1. Minimum clinical recommendations of the European Society of Medical Oncology (ESMO) / Editors : Russian translation: professional Soulanges, CMN Dassow, Professor Nieprawadziwe. - M.: Publishing group of the Russian oncological scientific center named. Non Russian Academy of medical Sciences, 2010; 2. Guidelines for chemotherapy of neoplastic diseases. Edited Perevozchikova NI - 3rd ed., supplementary and processed): Practical medicine, 2011. - 512 S.).
However, passive immunotherapy ready cytokines has some significant drawbacks:
strong side effects, such as poisoning of the body, fever, cirrhosis of liver, adverse effects on the fetus and the immune status of the offspring;
in the patients body stops the production of cytokines own immune system, organs of the immune system atrophy, depression of immunity;
the duration of clinical effect is directly related to the total duration of treatment, as after the drug soon relapses of the disease;
to receive the benefits of further treatment is necessary to increase the dose of cytokines, which increases the toxic effect p is aparatow.
It is also known cancer treatment and immunodepressed active immunotherapy with vaccines Seu"containing lipopolysaccharide (Fighters A.G., Livland V.G. Treatment of dysbiosis: Food, medicines and biologically active additives. - SPb.: Publishing House "Neva"; M: OLMA-PRESS invest, 2003. - 384 S.).
The disadvantage of this treatment is that the vaccine has caused severe adverse reactions, primarily associated with increasing temperature, the poisoning of the body and the development of cirrhosis of the liver.
The task of the invention consists in stimulating the immune system of the patient using natural mechanisms developed in the course of human evolution, and maintenance of treatment without harmful side steps on his body.
The task is solved in that the treatment of patients with cancer and/or immunodepressed produce drugs that cause active cell immunostimulation, which according to the invention is in the form of lyophilized lysate gram-negative bacteria of the family intestinal. The key point is that these drugs should be placed in the capsule, preventing the absorption of the active substance in the upper intestine, for example in gelatin capsules. The effect of active immunotherapy quickly comes when nebolshaya, therefore, it should be applied at early stages of development of malignant tumors or after surgical removal of the tumor. Immunotherapy in this case focused on the prevention of recurrence and metastasis. In addition, after removal of tumors of the large decreases cancer intoxication, which strongly inhibited the immune system, and reduces the duration of active immunotherapy.
Thus, the proposed method has the following advantages:
1. therapeutic effect is achieved by the stimulation of the immune system of the patient using natural mechanisms developed in the course of human evolution.
2. There are no adverse reactions, which allows for long-term treatment as in-patient and outpatient settings.
3. Unlike known methods, the organs of the immune system not only atrophy, and contrast - enhanced, exaggerated.
4. No contraindications.
The microorganisms of the family of the intestinal, the main representative of which is Esherichia coli, grown by the method of deep cultivation in a nutrient medium Endo for Escherichia coli (e.g., NPO "Nutrient medium", Makhachkala).
Sowing cultivated 18-24 hours at 36°C.
The culture fluid (QOL) with microorganisms subjected centres is Pirovano. Bacterial cells are lysed using a lytic enzyme trypsin (2.1 wt.%) for 4 hours at a temperature of +37°C.
The obtained enzyme lysate of bacterial cells subjected to freeze-drying in a drying apparatus for drying whey.
The resulting lyophilisate is mixed with sterile excipients: zeolite, hydrolyzed soy flour (POL), calcium stearate (CS).
The drug contains (wt.%): zeolite 70-80; hydrolysates of soy flour 15-20; calcium stearate 0.5 to 1.5; lytic enzymes of 0.05 to 3.5; lyophilized lysate of cells of microorganisms - the rest.
Under sterile conditions the drug in a hard gelatin enteric-soluble capsules, covered with acid-protective layer. The amount of the drug in the capsule must be such that the content of the lyophilisate in each capsule was 6 mg
Patient W, 76 years of age.
on March 23, 2011 blood prostatespecific antigen (PSA): 8 ng/ml.
March 24, 2011 reception of oncourologist. When the finger examination of the prostate gland is determined by cartilage density formation of the left lobe of the prostate.
March 30, 2011, ultrasound, transrectal us. Prostate gland: Size 66×42×61 mm Volume gland 84,5 cm3. The capsule can be traced all over, smooth and clear. Echo fabrics mixed, heterogeneous structure. Isoechogenic node in the rights of the th Central zone 14 mm, in the left and the transition zone for 26 mm Present in both halves of 1-2 mm In the posterior peripheral zone of the left section 23×6×4 mm, reduced echogenicity, irregular shape, without clear contours with increased vascular pattern. Conclusion: the outer hyperplasia identifying hypoechoic area in the left peripheral zone.
March 31, 2011, needle biopsy of the prostate with 12 points under the control of transrectal us. Patologicheskoe conclusion: melkoatsinarnaya moderately differentiated prostatic carcinoma low grade, Gleason sum 5 points (2+3), on the background of BPH and chronic prostatitis.
April 1, 2011 enrollment of oncourologist. Diagnosis: prostate cancer stage III, group II, comorbidities - dishormone hypertrophy of prostate cancer and chronic prostatitis.
In the treatment of the proposed method, the patient took lyophilized lysate gram-negative bacteria of the family of intestinal dose of 6 mg, placed in gelatin capsules are prepared as described in example 1 for 3 months without a break, daily one capsule in the morning on an empty stomach. While traditional methods of treatment of oncological diseases (passive hormonal therapy, chemotherapy, radiation therapy, surgery, and other) were not applied.
Istace the AI 3-month treatment the patient underwent a medical examination.
August 18, 2011 the analysis of the PSA blood test and 6.6 ng/ml
August 19 2011, ultrasound, transrectal us. Prostate gland: Size 67×42×57 mm, Volume of a gland of an 80.2 cm3. The capsule can be traced throughout the stretch, smooth, clear. The echogenicity of the tissue is increased, the structure is heterogeneous. Exterior isoechogenic nodes to the right for 20 mm, left 31 mm. Present on a path of nodes, single cysts in the thick of nodes up to 3 mm In the posterior peripheral zone segment decreased echogenicity left 14×6×9 mm without clear contours, identifying vessels. The vascular pattern of the prostate is not modified. Seminal vesicles normal size, symmetrical structure is not changed. The lumen of the veins around the prostate was normal.
Given the presence of residual tumors of the prostate and the absence of any complications, it was decided to continue the treatment by the proposed method without interruption.
Control examination after 4.5 months of treatment.
on October 19, 2011 analysis of the PSA blood test and 6.7 ng/ml
November 1, 2011, ultrasound, transrectal us. Prostate spherical shape. Contours equal, precise. Length of 58 mm, a thickness of 47 mm, width 65 mm Volume 92,14 cm3. The capsule is not broken, irregularly thickened sealed. "Zonal differentiation" of the cancer is determined. The echogenicity of the parenchyma uneven. Structure p is estatales cancer: with the presence of Hypo - and hyperechoic areas, with hyperechoic inclusions in both lobes. In the left lobe mud lazerette nodal education 39 mm in diameter isoechogenic structure, with clear smooth contours, homogeneous, hypoechoic capsule surrounding education. Clearly visible hyperechoic surgical capsule. The peripheral part of the gland without focal changes irregular echogenicity. Along the prostatic part of the urethra and in periuretralnuu region lazerous hyperechoic inclusions. Peripatetically fiber is not changed, the normal echogenicity. Mode DRC - EDC pathological vascularization is not detected, the entities identified in previous surveys (with transrectal us from 3.03.2011, and, 19.08.2011), these areas are not detected. Conclusion: volumetric enlargement of the prostate (BPH).
Mood, sleep and appetite of the patient after treatment, the proposed method has improved. Before treatment experienced lack of energy, constant fatigue and was getting tired easily at the slightest exertion.
Blood counts after treatment has improved, the number of leukocytes WBC (overall immunity) increased to 4.81·109/l to 6,88·109/l, monocytes MONO (indicator of cell-mediated immunity) from 7.85% to 10.6%.
Indicators of liver function tests consistently good.
|The beginning of the treatment||The end of the treatment|
|Timol||0,6 ED||0,4 ED|
November 2, 2011 reception of oncourologist. Diagnosis: prostate cancer stage III, group III, comorbidities - dishormone hypertrophy of prostate cancer and chronic prostatitis.
The treatment offered by way stimulates the production of anti-inflammatory and antitumor cytokines of the immune system of the body, and the organs of the immune system are amplified, exaggerated. Cytokines formed by its own immune system, no toxic effects.
Patient F., 70 years. Diagnosis: chronic athlete's skin of the foot and nail, immunosuppression.
After treatment the patient of the proposed method over one month installed cure fungal diseases of the skin of the foot and nail. No relapse was observed during the year.
Blood counts after treatment has improved, the number of leukocytes WBC (overall immunity) increased from 3,62·109/l to 5,74·10
Patient, 64 years. Diagnosis: recurrent shingles - Herpes zoster, immunosuppression.
After treatment the patient of the proposed method within one month of relapses no more than one year.
Blood counts after treatment has improved, the number of leukocytes WBC (overall immunity) increased from 3,55·109/l to 6.81·109/l, monocytes MONO (indicator of cell-mediated immunity) of 6.25% to 8.31%.
Mandatory treatment approach is the following:
- correction of dysbacteriosis of the intestine to recover the intake of lipopolysaccharides (LPS) in the natural way;
- intake of antioxidants (vitamins E, A, C, beta-carotene) to save from destruction connections NO;
Inbox full of protein foods to ensure the intake of essential amino acids L-arginine, which is the starting material for formation of compounds of NO in the body;
- the diet should be rich in pectin and fiber (vegetables, fruits, bran cereals) to stimulate the development of the normal intestinal microflora;
acceptance of other vitamins and minerals to improve metabolic processes.
The proposed method is promising and harmless to about what ractice and treatment of cancer, immunosuppressive conditions, viral infections (e.g. herpes). The proposed method can be used in the treatment of patients with malignant tumors as monotherapy, with tumors of large size in the combined treatment (surgery and postoperative active immunotherapy), as well as immunosuppression, viral and fungal diseases.
A method of treating patients with cancer, including treatment with drugs that cause the active cell immunostimulation, characterized in that such drugs are in the form of lyophilized lysate gram-negative bacteria of the family of intestinal placed in gelatin capsules, and is correction of dysbiosis, intake of antioxidants and full of protein that contains the amino acid L-arginine, plant foods rich in pectin and fiber, and vitamins and minerals.
SUBSTANCE: developed agent contains trophoblastic β-1-glycoprotein (TBG), immunoglobulin (Ig) and additionally contains tetrapeptide H-Tyr-X-Y-Glu-OH, wherein X - Gln and/or Glu, Y - Cys (acm) and/or Cys.
EFFECT: effective treatment of autoimmune diseases by single doses containing TBG 1 mg, Ig 19 mg and tetrapeptide 20 mg.
6 tbl, 13 ex
SUBSTANCE: group of inventions refers to veterinary science and aims at normalising metabolic processes, stimulating immune system and blocking mechanisms of infectious process with a risk of endogenous infection activation. A method for producing a combination immunometabolic preparation with anti-infectious activity involves dissolving succinic acid and levamisole in demineralised water with formalin added. According to the other aspect of the invention, the immunometabolic preparation additionally contains polyethylene glycol. The ingredients are used in the declared ratio.
EFFECT: using this group of inventions provides producing an injection form of the immunometabolic preparation with anti-infectious activity.
2 cl, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the chemical-pharmaceutical industry and represents a method of obtaining a complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties, which includes mixing succinic acid, levamisole and formalin in distilled water with the following component ratio, wt %: levamisole - 3.0%-3.5%; succinic acid - 2.0%-2.5%; formalin - 0.3%-0.5%, distilled water - the remaining part; sterilisation of the solution by autoclaving is performed in a mode of 1 atm for 20 minutes.
EFFECT: elaboration of the method of obtaining the complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties.
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed group of inventions relates to medicine, namely to therapy and immunology, and deals with treatment of autoimmune diseases. For this purpose 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid or its salt is introduced in the form of a combination or a pharmaceutical composition with one or more of TNFα inhibitors.
EFFECT: invention provides efficient treatment of autoimmune diseases due to synergic action of the said components.
6 cl, 1 ex, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry, namely to a personal preparation from earthworms for treatment of diabetes. The method of obtaining the personal preparation from earthworms for treatment of diabetes includes placement of sexually mature earthworms in a medium, consisting of organics, which additionally contains a solution of a patient's urine, after that, the sexually mature earthworms are removed and for 3 months each 7-10 days fresh organic food is added to the remaining mass, after that, the sexually mature earthworms are separated, placed in a reservoir and sprayed with an alcohol solution, mixed, poured with the alcohol solution and placed into dark place under the specified temperature, with the solution being mixed daily, with further separation of the extract from the sediment. The personal preparation for treatment of diabetes.
EFFECT: application of the described above preparation increases efficiency of diabetes treatment.
3 cl, 3 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, more specifically to a pharmaceutical composition possessing antithrombotic, thrombolytic, immunomodulatory, anti-inflammatory action, normalising lipid and carbohydrate metabolism, more specifically to the pharmaceutical composition of the substance Pijavitum (hereinafter referred to Pijavitum) made from lyophilised medicinal leech. The above pharmaceutical composition is presented in the form of an enteric coated tablet.
EFFECT: coating prevents the active ingredients of Pijavitum from destruction under action of the enzymes and acid medium of the stomach.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new antineoplastic drug representing 2-isobutyl-4,6-dimethyl-5-oxypyrimidine of the general formula I specified below. The drug may be used for an adjuvant antineoplastic immune therapy. The invention also refers to a method for preparing 2-isobutyl-4,6-dimethyl-5-oxypyrimidine. According to the method, isocaproic acid amide reacts in ice-cold acetic acid with chloracetyl acetone to form the respective oxazole which reacts with aqueous ammonia which leads to preparation of the above compound.
EFFECT: what is disclosed is a manifested tumour growth inhibition with no signs of the toxic effect on somatic characteristics of tumour-carrier mice.
3 cl, 9 tbl, 6 ex
SUBSTANCE: what is presented is a method for simulating a delayed hyperresponsiveness to mycobacteria bovis. Avirulent mycobacteria bovis of the strain BCG are administered intracutaneously to albino guinea pigs produced by consanguineous mating of brother x sister (F2); that is followed by forming a group (groups) of animals showing various extents of an inflammatory response in reaction to the intracutaneous administration of mycobacteria bovis of the strain BCG 30-35 days later.
EFFECT: method is effective in studying the mechanisms of the delayed hyperresponsiveness and assessing the efficacy of antituberculosis agents.
2 tbl, 5 ex
SUBSTANCE: agent, having adaptogenic and immunomodulating activity, containing medicinal marigold flower heads; rhaponticum carthamoides root and rhizome; horse-heal rhizome; nutmeg fruit; cardamom fruit; calamus root; sweet weed root; ginger rhizome; knotgrass; cinnamon bark; pomegranate; long red pepper; juniper fruit; leather bergenia black leaves; chitosan, taken in a defined amount.
EFFECT: agent has marked adaptogenic and immunomodulating activity.
SUBSTANCE: group of inventions relates to medicine, in particular to gastroenterology, and deal with treatment of ulcerative colitis and Crohn's disease. Method of treatment includes introduction into organism of therapeutically efficient quantity of attaching cells from placenta, cultivated in such a way as not to differentiate into adipocytes or osteocytes. Also claimed is application of said cells for obtaining medication, intended for treatment of ulcerative colitis or Crohn's disease. Claimed produced product for treatment of ulcerative colitis or Crohn's disease includes in packing form pharmaceutically efficient quantity of said cells.
EFFECT: inventions ensure essential reduction of inflammatory process in colon in modelling of said diseases, as well as due to pathological mechanisms of treatment in addition to T-lymphocyte suppression.
31 cl, 5 ex, 12 tbl, 16 dwg
SUBSTANCE: strain Lactobacillus fermentum RCM B-2793D is proposed, which has antagonistic activity against pathogenic and opportunistic microorganisms. Also the consortium of strains of Lactobacillus fermentum RCM B-2793D, Lactobacillus crispatus VKM B-2727D, Lactobacillus gasseri VKM B-2728D, Lactobacillus plantarum VKM B-273D is proposed, which has probiotic action and is used for production of bacterial preparations and lactic acid products of functional nutrition. The consortium has a higher antagonistic activity against pathogenic and opportunistic microorganisms compared to individual strains of lactobacilli in its composition.
EFFECT: group of inventions enables to expand the range of probiotic strains, the means for prevention and treatment of mastitis in breastfeeding mothers.
2 cl, 1 dwg, 5 tbl, 12 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to biotechnology. There are presented strain Enterococcus faecium 8G-1 (NRRL B-50173), strain Enterococcus faecium 8G-73 (NRRL B-50172) and strain Bacillus pumilus 8G-134 (NRRL B-50174) providing the improvement in ruminant's health. Any of the above strains or a combination thereof in a combination with monensin are used to prepare a formulation providing the improvement in ruminant's health. There are also presented versions of the method for the improvement in ruminant's health involving administering the above strains either alone, or in a combination with monensin as well. What is also provided is a method for producing a microorganism administered into ruminants.
EFFECT: group of inventions can be used for treating or preventing acidosis, for improving ruminant's health indicators and/or ensuring higher productiveness.
18 cl, 8 dwg, 11 tbl, 4 ex
FIELD: packaging industry.
SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.
EFFECT: invention enables to extend the shelf life of the probiotic product.
13 cl, 1 dwg, 1 tbl, 4 ex
SUBSTANCE: group of inventions refers to medicine, namely to medical microbiology, and can be used for treating intestinal yersiniosis, or pseudotuberculosis, or salmonellosis experimentally. That is ensured by simulating one of the above pathologies in experimental animals followed by oral administration of therapeutic preparations in therapeutically effective doses with controlling the content of pathological microflora for a period of time providing elimination of the disease. Stimbifid or a culture fluid of lactic acid bacilli is administered orally as the therapeutic preparation into each animal for the first 2 hours after infection once a day as a monotherapeutic preparation promoting the colonisation resistance of the intestinal mucosa to an agent. Stimbifid is administered into each animal in a dose of 13 mg for 5 days from the moment of the infection, while the culture fluid is administered in an amount of 0.2 ml throughout 7 days from the moment of the injection. What is also presented is a method for preparing an agent for treating intestinal yersiniosis, or pseudotuberculosis, or salmonellosis experimentally.
EFFECT: group of inventions provides a high percentage of pathology elimination by using the prebiotic preparation and the liquid probiotic complex with no accompanying negative consequences.
4 cl, 3 tbl, 3 ex
FIELD: food industry.
SUBSTANCE: invention relates to functional food products and represents a method for production of a non-aqueous health-improving product that is administrated in the form of drops and contains strain of lactic bacteria suspended in vegetable food oil; vegetable food oil is mixed with vitamin D; Lactobacillus rhamnosus GG lactic bacteria are suspended in the produced oil mixture.
EFFECT: invention ensures combination of beneficial effects of the proposed composition ingredients and easiness of the latter dosing during intake.
11 cl, 1 dwg, 1 ex
FIELD: veterinary medicine.
SUBSTANCE: aminoseleton is administered subcutaneously to animals in combination with symptomatic preparations - magestrofan, uteroton, tetragidrovit and etiotropic preparation. As etiotropic preparation the combination antimicrobial agent is used containing cefotaxime, neomycin, prednisolone, emulsifier, monoglyceride, vaseline oil, in the following ratio of components, wt %: cefotaxime - 7.0%, neomycin - 1.0%, prednisolone - 0.2%, emulsifier - 3.0%, monoglyceride - 1.0%, vaseline oil to 100.0, which is administered intrauterine 2-3 times with the 24-hour intervals in a dose of 20 ml.
EFFECT: invention improves therapeutic efficacy in chronic and latent endometritis.
3 tbl, 3 ex
SUBSTANCE: strain Lactobacillus acidophilus No. 9-PS has biochemical activity and high acidity. The strain is deposited in the Departmental collection of beneficial microorganisms for agricultural purposes of Russian Agricultural Academy (RCAM) under the registration number of RCAM01850. The strain may find application in prevention and correction of disorders of microbiocenosis of the gastrointestinal tract.
EFFECT: invention enables to increase growth of mucous cultures of lactic acid bacteria and accelerates the process of colonisation of intestinal with beneficial microflora.
2 tbl, 3 ex
SUBSTANCE: invention relates to industrial microbiology, namely to a method of obtaining a composition, intended for prevention of a cow milk protein allergy (CMPA) and a higher sensitivity to allergens in newborn babies and infants. The method includes a stage of milk substrate bioconversion by means of a culture of Bifidobacterium breve BBC50 strain, deposited on May 31 1999 in the National Collection of Cultures of Microorganisms (CNCM) under the number I-2219, by keeping a substrate in contact with the strain culture under conditions unfavourable for production of an acid by the strain.
EFFECT: application of the claimed method makes it possible to obtain the composition, efficient for prevention of the allergy to cow milk proteins and a higher sensitivity to allergens in newborn babies and infants.
10 cl, 5 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.
EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.
7 cl, 1 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to industrial microbiology, namely to creating of strain Lactobacillus plantarum specified in a group consisting of Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL-9, DSM 15312, Lactobacillus plantarum HEAL-19, DSM 15313, and Lactobacillus plantarum HEAL-99, DSM 15316, for increasing the gastrointestinal bacterial diversity. The above strains are applicable to prevent developing low bacterial diversity (LBD) in a healthy individual, to prevent developing translocation, large intestinal bacterial overgrowth (LIBO) or small intestinal bacterial overgrowth (SIBO) in the individual with LBD, to prevent developing translocation in the individual with LIBO or SIBO.
EFFECT: using the above strains enables providing more effective prevention or treatment of gastrointestinal infections and a possibility to enlarge the bacterial diversity.
16 cl, 1 tbl, 1 dwg, 1 ex
FIELD: biotechnology, microbiology, medicine.
SUBSTANCE: invention relates to the strain Lactobacillus paracasei CNCM I-2116 used for diarrhea prophylaxis causing by pathogenic microorganisms. Supernatant of this strain culture elicits ability to prevent colonization of intestine with pathogenic microorganisms causing diarrhea also and this strain is designated for preparing agent used for prophylaxis and/or treatment of disorders associated with diarrhea. Agent for oral administration represents therapeutically effective dose of the strain L. paracasei CNCM I-2116 or supernatant of its culture and acceptable foodstuff. Invention provides the enhanced viability of the strain in its applying and effectiveness in prophylaxis of adhesion to intestine cells and invasion to intestine cells of pathogenic microorganisms causing diarrhea.
EFFECT: valuable medicinal properties of strain.
5 cl, 8 dwg, 10 ex